On February 8, the National Health Insurance Administration issued a notice requiring all provinces to temporarily include the two drugs of deuterium remidvir hydrobromide tablets and pre-nortevir tablets/ritonavir tablets into the payment scope of the province's basic medical insurance fund, and pay until March 31, 2023.
On January 29, 2023, the State Food and Drug Administration conditionally approved the launch of the new coronavirus infection treatment drug deuterium remidevir hydrobromide tablets (trade name: Mindwei) declared by Shanghai Wangshi Biomedical Technology Co., Ltd. and the combination packaging of the new coronavirus infection treatment drug Senotervir tablets / ritonavir tablets (trade name: Synoxin) declared by Hainan Simcere Pharmaceutical Co., Ltd.
The person in charge of the Department of Medical Administration of the National Health Insurance Administration introduced that according to the National Health Commission's "Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10)", the above two drugs belong to the scope of the 10th edition of the diagnosis and treatment plan. On January 30, the National Health Insurance Administration issued a document requiring all provincial medical security departments to temporarily include the two drugs of deuterium remidvir hydrobromide tablets and prenotevir tablets/ritonavir tablets into the payment scope of the basic medical insurance fund of the province in accordance with the requirements of the Notice of the National Health Insurance Administration, the Ministry of Finance, the National Health Commission, and the National Disease Control Administration on Optimizing the Medical Security Policy for Treatment Costs of Patients with Novel Coronavirus Infection after the Implementation of "Class B and B Tube" (Medical Insurance Fa [2023] No. 1). Payment is until March 31, 2023. At the same time, the medical insurance bureaus of relevant provinces are required to perform their duties as drug price authorities in accordance with the law, do a good job in accepting and guiding the initial quotations of relevant drugs in accordance with the "Guidelines for the Formation of Prices of New Crown Treatment Drugs (Trial)", disclose price composition information, and accept social supervision.
At present, all domestic new crown treatment drugs approved for marketing have been included in the scope of medical insurance payment. Among them, traditional Chinese medicine "three drugs and three formulas" (as shown in the figure below) and azvudine tablets have been officially included in the medical insurance drug list, and drugs such as deuterium remidevir hydrobromide tablets and pre-nuoteravir tablets/ritonavir tablets combination packaging have been temporarily included in the scope of medical insurance payment.
National Medical Insurance Administration: The first quotation of new crown treatment drugs is accepted centrally and used nationwide
The National Medical Security Administration recently issued a notice on the "Guidelines for the Formation of New Crown Treatment Drugs (Trial)". According to the notice, in order to adapt to the new situation and new tasks of the prevention and control of the new crown virus infection epidemic, focus on "maintaining health and preventing severe diseases", support the diversified supply of new crown treatment drugs, give full play to the decisive role of the market, better play the role of the government, stimulate innovation vitality, safeguard the public interest, strengthen the supervision of the price behavior of new crown treatment drugs, and promote the fair access of new crown treatment drugs, this guideline is formulated and trialed in accordance with the Price Law of the People's Republic of China and the Drug Administration Law of the People's Republic of China. The guidelines provide for 13 aspects, including the scope of application.
The Guidelines stipulate that from January 1, 2023, the national drug administration will apply to new crown treatment drugs approved for marketing (including conditional listing). "New crown treatment drugs" as used in these guidelines refers to drugs that directly target the new crown virus and have the effect of blocking infection or virus replication, excluding general drugs that relieve symptoms such as high fever, cough, and pain, as well as symptomatic treatment such as immune regulation, anticoagulation, and life support. The new crown treatment drugs implement market-regulated prices in accordance with the law, and pharmaceutical companies independently set sales prices. Pharmaceutical enterprises should follow the principles of fairness and legality, good faith, quality and price, comprehensively consider factors such as production and operation costs, market supply and demand, clinical treatment value and other factors to formulate prices, strive to improve production and operation to reduce costs, fully consider the role of sales scale on production and operation costs, dynamically adjust prices, take the initiative to assume social responsibility, and keep the profit level within a reasonable range. The medical insurance department actively supports the innovation and development of pharmaceutical enterprises, encourages pharmaceutical enterprises to develop and produce new crown treatment drugs, respects the specific prices independently set by pharmaceutical enterprises, deepens the reform of simplifying administration and delegating power, combining management and management, and optimizing services, does not set government pricing or administrative approval in accordance with the law, focuses on providing guidance for pharmaceutical enterprises to formulate the price of new crown treatment drugs, improves the overall efficiency of new crown treatment drugs on the network, and promotes the open, transparent and reasonable exercise of independent pricing rights by strengthening before, during and after supervision. The new crown treatment drugs entered the domestic centralized pharmaceutical procurement market for the first time, and the centralized acceptance of the first quotation was implemented and used nationwide.
After taking the initiative of various localities, the medical insurance bureaus of six provinces, including Beijing, Tianjin, Hebei, Shanghai, Jiangsu and Sichuan Province, will be the first price acceptance units of new crown treatment drugs, and enterprises can independently choose one eligible acceptance unit to declare the initial price.
Real biological azvudine tablets: 350 yuan / course of treatment after medical insurance
On January 18, 2023, at the press conference on the adjustment of the national medical insurance drug list, it was announced that azvudine tablets were included in the national medical insurance drug list, with an average of 445 yuan per course (540 yuan before medical insurance and 350 yuan after medical insurance). On July 25, 2022, Henan Real Biotechnology Co., Ltd.'s azvudine tablets were approved to add the indication of new coronavirus pneumonia.
Simcere Pharmaceutical's Xiantevir tablets/ritonavir tablets: The initial price is 750 yuan / box
On January 30, the Beijing Municipal Medical Security Bureau announced that the first price of Hainan Simcere Pharmaceutical Co., Ltd.'s new crown treatment drug Xianoxin tablets / ritonavir tablets combination packaging (Xiannoxin) is 750 yuan / box, and one box is a course of treatment. Synoxin received conditional approval from the State Food and Drug Administration on January 29 this year.
Mindevin hydrobromide deuterium remidevir tablets: the first price is 795 yuan / box
On February 3, the Sichuan Provincial Medical Security Bureau officially announced the first price of deuterium remidevir hydrobromide tablets (Mindwei) at 795 yuan / box, and the new domestic new crown treatment drugs are expected to quickly enter the Chinese market. On January 29, the oral small molecule new coronavirus infection treatment drug Mindewei of Shanghai Wangshi Biomedical Technology Co., Ltd., a subsidiary of Junshi Biotechnology, was conditionally approved for marketing by the State Food and Drug Administration in accordance with the emergency review and approval of the special drug approval procedure.
Source: National Health Insurance Administration
Information Collection: Wei Jianjun